Correlation Between Pfizer and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both Pfizer and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pfizer and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pfizer Inc and Crispr Therapeutics AG, you can compare the effects of market volatilities on Pfizer and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and Crispr Therapeutics.

Diversification Opportunities for Pfizer and Crispr Therapeutics

-0.35

Correlation Coefficient

Pfizer  Crispr Therapeutics

Very good diversification

The 3 months correlation between Pfizer and Crispr is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Pfizer i.e., Pfizer and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Pfizer and Crispr Therapeutics

Considering the 90-day investment horizon Pfizer Inc is expected to under-perform the Crispr Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Pfizer Inc is 2.29 times less risky than Crispr Therapeutics. The stock trades about -0.13 of its potential returns per unit of risk. The Crispr Therapeutics AG is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  4,894  in Crispr Therapeutics AG on September 13, 2024 and sell it today you would lose (354.00) from holding Crispr Therapeutics AG or give up 7.23% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Pfizer Inc  vs.  Crispr Therapeutics AG

Pfizer Inc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Crispr Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Crispr Therapeutics is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Pfizer and Crispr Therapeutics

The main advantage of trading using opposite Pfizer and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind Pfizer Inc and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.